keyword
MENU ▼
Read by QxMD icon Read
search

Aromatase inhibitor

keyword
https://www.readbyqxmd.com/read/29923063/persistent-major-alopecia-following-adjuvant-docetaxel-for-breast-cancer-incidence-characteristics-and-prevention-with-scalp-cooling
#1
M Martín, J C de la Torre-Montero, S López-Tarruella, K Pinilla, A Casado, S Fernandez, Y Jerez, J Puente, I Palomero, R González Del Val, M Del Monte-Millan, T Massarrah, C Vila, B García-Paredes, J A García-Sáenz, A Lluch
BACKGROUND: Persistent alopecia (PA) after docetaxel has been recently described. The aim of our study is to establish the incidence and characteristics of PA following adjuvant docetaxel for breast cancer (BC) and to test the ability of scalp cooling in prevention. PATIENTS AND METHODS: BC patients receiving adjuvant chemotherapy followed or not by endocrine therapy (and a control group receiving only endocrine therapy) were interviewed in a single institution at 1...
June 19, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29921733/aromatase-acetylation-patterns-and-altered-activity-in-response-to-sirtuin-inhibition
#2
Kevin Pruitt, Deborah Molehin, Isabel Castro-Piedras, Monica Sharma, Souad R Sennoune, Daphne Arena, Pulak R Manna
Aromatase, a cytochrome P450 member, is a key enzyme involved in estrogen biosynthesis and is dysregulated in the majority of breast cancers. Studies have shown that lysine deacetylase inhibitors (KDI) decrease aromatase expression in cancer cells, yet many unknowns remain regarding the mechanism by which this occurs. While advances have been made to clarify factors involved in the transcriptional regulation of the aromatase gene (CYP19A1). Yet, despite aromatase being a primary target for breast cancer therapy, its post-translational regulation has been virtually unexplored...
June 19, 2018: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/29921434/no-362-ovulation-induction-in-polycystic-ovary-syndrome
#3
David S Smithson, Tannys D R Vause, Anthony P Cheung
OBJECTIVE: To review current non-pharmacologic and pharmacologic options for ovulation induction in women with polycystic ovary syndrome (PCOS). OPTIONS: This guideline reviews the evidence for the various options for ovulation induction in PCOS. OUTCOMES: Ovulation, pregnancy and live birth rates, risks, and side effects are the outcomes of interest. EVIDENCE: Published literature was retrieved through searches of Medline using appropriate controlled vocabulary and key words spanning from 2000 to 2016...
July 2018: Journal of Obstetrics and Gynaecology Canada: JOGC, Journal D'obstétrique et Gynécologie du Canada: JOGC
https://www.readbyqxmd.com/read/29917140/predictive-biomarkers-for-endocrine-therapy-retrospective-study-in-tamoxifen-and-exemestane-adjuvant-multinational-team-trial
#4
Antonia K Roseweir, Lindsay Bennett, Ashley Dickson, Kelvin Cheng, Mary-Anne Quintayo, Jane Bayani, Donald C McMillan, Paul G Horgan, Cornelis J H van de Velde, Caroline Seynaeve, Annette Hasenburg, Dirk G Kieback, Christos Markopoulos, Luc Y Dirix, Daniel W Rea, Elizabeth A Mallon, John M S Bartlett, Joanne Edwards
Background: Aromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor-positive breast cancer. The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy with sequential therapy of tamoxifen followed by exemestane. The trial failed to show a statistically significant difference between treatment arms. A robust translational program was established to investigate predictive biomarkers. Methods: A tissue microarray was retrospectively constructed using a subset of patient tissues (n = 4631) from the TEAM trial (n = 9766)...
June 1, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29912452/genetic-predictors-of-response-to-acupuncture-for-aromatase-inhibitor-associated-arthralgia-among-breast-cancer-survivors
#5
Timothy J Genovese, Jun J Mao
Objective: To evaluate the associations between polymorphisms in two genes, catechol-O-methyltransferase and T-cell leukemia/lymphoma 1 A, and acupuncture-mediated pain reduction among breast cancer survivors with aromatase inhibitor-associated arthralgia. Design, Setting, and Subjects: Biospecimens were obtained from 38 patients enrolled in a clinical trial of acupuncture for aromatase inhibitor-associated arthralgia in postmenopausal hormone receptor-positive breast cancer survivors...
April 17, 2018: Pain Medicine: the Official Journal of the American Academy of Pain Medicine
https://www.readbyqxmd.com/read/29909753/alteration-at-transcriptional-level-of-cardiac-renin-angiotensin-system-by-letrozole-treatment
#6
Shahnaz Shekarforoush, Farhad Koohpeyma, Fatemeh Safari
INTRODUCTION: The use of aromatase inhibitors (AIs) for breast cancer led to a marked change in ventricular function. Since accumulating evidence indicates that overactivation of the cardiac renin-angiotensin system (RAS) plays an important role in the development of cardiovascular diseases such as hypertrophy and remodelling, we aimed to investigate whether letrozole alters the transcription level of RAS related genes in the cardiac tissue. METHODS: Twenty four rats were randomly divided into four groups (n = 6 per group): two groups were letrozole treated (1 and 2 mg/kg/day orally), one group was vehicle treated (DMSO) and one group was the control group without any treatment...
June 17, 2018: Acta Cardiologica
https://www.readbyqxmd.com/read/29909262/behavioral-evidence-for-sex-steroids-hypersensitivity-in-castrated-male-canaries
#7
Olesya Shevchouk, Samar Ghorbanpoor, Ed Smith, Philippe Liere, Michael Schumacher, Gregory F Ball, Charlotte A Cornil, Jacques Balthazart
In seasonally breeding songbirds such as canaries, singing behavior is predominantly under the control of testosterone and its metabolites. Short daylenths in the fall that break photorefractoriness are followed by increasing daylengths in spring that activate singing via both photoperiodic and hormonal mechanisms. However, we observed in a group of castrated male Fife fancy canaries maintained for a long duration under a short day photoperiod a large proportion of subjects that sang at high rates. This singing rate was not correlated with variation in the low circulating concentrations of testosterone...
June 14, 2018: Hormones and Behavior
https://www.readbyqxmd.com/read/29909120/integrated-in-silico-in-vitro-strategy-for-screening-of-some-traditional-egyptian-plants-for-human-aromatase-inhibitors
#8
Hend M Dawood, Reham S Ibrahim, Eman Shawky, Hala M A Hammoda, Aly M Metwally
ETHNOPHARMACOLOGICAL RELEVANCE: Aromatase enzyme (CYP19) is widely known as a critical target protein for treating hormone-dependent breast cancer. Natural products from traditional medicinal plants continue to be an active source of aromatase inhibitors. Meanwhile, high cost of experimental work and low hit rate associated with HTS have stimulated the implementation of in-silico virtual screening to resolve these pitfalls, where coupling of both classical wet lab procedure and VS may offer a more deepened access to bioactive compounds with less work and time waste...
June 14, 2018: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/29907661/nlrp3-in-somatic-non-immune-cells-of-rodent-and-primate-testes
#9
Lena Walenta, Nina Schmid, J U Schwarzer, Frank-Michael Köhn, Henryk Urbanski, Ruediger Behr, Leena Strauss, Matti Poutanen, Artur Mayerhofer
NLRP3 is part of the NLRP3 inflammasome and a global sensor of cellular damage. It was recently discovered in rodent Sertoli cells. We investigated NLRP3 in mouse, human and non-human primate (marmoset and rhesus macaque) testes, employing immunohistochemistry. Sertoli cells of all species expressed NLRP3, and the expression preceded puberty. In addition, peritubular cells of the adult human testes expressed NLRP3. NLRP3 and associated genes (ASC, CASP1, IL1B) were also found in isolated human testicular peritubular cells (HTPCs) and the mouse Sertoli cell line TM4...
June 15, 2018: Reproduction: the Official Journal of the Society for the Study of Fertility
https://www.readbyqxmd.com/read/29890985/effect-of-neuromuscular-taping-on-musculoskeletal-disorders-secondary-to-the-use-of-aromatase-inhibitors-in-breast-cancer-survivors-a-pragmatic-randomised-clinical-trial
#10
Inmaculada Conejo, Bella Pajares, Emilio Alba, Antonio Ignacio Cuesta-Vargas
BACKGROUND: Aromatase inhibitors reduce breast cancer recurrence rates in postmenopausal women by about 30% compared with tamoxifen while treatments differ. Unfortunately, nearly half of women taking AIs report AI-associated arthralgia (AIA), leading to therapy abandon in on third of patients, which could lead to cancer recurrence. The purpose of the current study was to evaluate the effectiveness of Neuromuscular Taping (NMT) in the treatment of AIA in women who have been treated of BC...
June 11, 2018: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/29889977/ovulation-induction-in-polycystic-ovary-syndrome
#11
Tom Tanbo, Jan Mellembakken, Sverre Bjercke, Eva Ring, Thomas Åbyholm, Peter Fedorcsak
The objective of this narrative review is to suggest a rational order of treatment choices in anovulatory women with polycystic ovary syndrome (PCOS), for whom a multitude of treatment options exist. In obese/overweight PCOS patients the importance of weight reduction should be stressed. Inositol, a dietary supplement with a documented effect on ovulation and without side effects in the doses recommended, may be suggested. Additional first line medical alternatives include insulin sensitizers, selective estrogen receptor modulators and aromatase inhibitors...
June 11, 2018: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/29886559/novel-therapy-for-male-hypogonadism
#12
REVIEW
Robert Carrasquillo, Kevin Chu, Ranjith Ramasamy
PURPOSE OF REVIEW: Hypogonadism and the treatment of low testosterone is increasingly a subject of medical inquiry and controversy. The few treatments that are FDA-approved such as testosterone topicals, injections, and pellets create significant demand from patients for treatments with more convenient means of administration, fewer adverse effects, and the ability to maintain male fertility. Off-label drugs are in abundant use for low testosterone, including selective estrogen receptor modulators, gonadotropins, and aromatase inhibitors...
June 9, 2018: Current Urology Reports
https://www.readbyqxmd.com/read/29886394/adjuvant-endocrine-therapy-in-premenopausal-patients-with-hormone-receptor-positive-early-breast-cancer-evidence-evaluation-and-grade-recommendations-by-the-italian-association-of-medical-oncology-aiom
#13
REVIEW
Stefania Gori, Fabio Puglisi, Michela Cinquini, Giovanni Pappagallo, Antonio Frassoldati, Laura Biganzoli, Laura Cortesi, Alba Fiorentino, Catia Angiolini, Corrado Tinterri, Andrea De Censi, Alessia Levaggi, Lucia Del Mastro
Premenopausal women with hormone receptor-positive early breast cancer are candidates for adjuvant endocrine therapy, as recommended by the major international guidelines. To date, adjuvant endocrine options for premenopausal women include tamoxifen with or without ovarian function suppression (OFS) or an aromatase inhibitor with OFS. Multiple strategies for endocrine treatment of premenopausal women with hormone-responsive breast cancer have been assessed, and the results of randomised clinical trials have been reported over the last years...
June 7, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29880014/targeting-tumour-re-wiring-by-triple-blockade-of-mtorc1-epidermal-growth-factor-and-oestrogen-receptor-signalling-pathways-in-endocrine-resistant-breast-cancer
#14
Ricardo Ribas, Sunil Pancholi, Aradhana Rani, Eugene Schuster, Stephanie K Guest, Joanna Nikitorowicz-Buniak, Nikiana Simigdala, Allan Thornhill, Francesca Avogadri-Connors, Richard E Cutler, Alshad S Lalani, Mitch Dowsett, Stephen R Johnston, Lesley-Ann Martin
BACKGROUND: Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+ ) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing the need for steroid hormones. Previously, we reported the anti-proliferative effect of everolimus (RAD001-mTORC1 inhibitor) with endocrine therapy in resistance models; however, potential routes of escape from treatment via ERBB2/3 signalling were observed...
June 8, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29879465/using-bayesian-evidence-synthesis-to-estimate-fracture-risk-associated-with-hormonal-therapy-in-breast-cancer
#15
Ava A John-Baptiste, Taryn Becker, Kinwah Fung, Lorraine L Lipscombe, Peter C Austin, Geoffrey M Anderson
OBJECTIVE: To conduct a Bayesian evidence synthesis using commonly available statistical procedures in order to estimate fracture risk for postmenopausal women undergoing hormonal therapy for breast cancer. STUDY DESIGN AND SETTING: Using linked administrative data, we conducted a retrospective cohort study of women age 66 or older diagnosed with stage I to III breast cancer in Ontario, Canada, between April 1, 2003 and February 28, 2010. We used data augmentation to perform Bayesian Cox regression of the hazard of a hip, spine or wrist/forearm fracture, adjusting for age, history of fragility fracture, corticosteroid use, osteoporosis, rheumatoid arthritis, dementia or diabetes diagnoses...
June 4, 2018: Journal of Clinical Epidemiology
https://www.readbyqxmd.com/read/29870471/the-role-of-androgens-in-the-treatment-of-genitourinary-syndrome-of-menopause-gsm-international-society-for-the-study-of-women-s-sexual-health-isswsh-expert-consensus-panel-review
#16
James A Simon, Irwin Goldstein, Noel N Kim, Susan R Davis, Susan Kellogg-Spadt, Lior Lowenstein, JoAnn V Pinkerton, Cynthia A Stuenkel, Abdulmaged M Traish, David F Archer, Gloria Bachmann, Andrew T Goldstein, Rossella E Nappi, Linda Vignozzi
OBJECTIVE: The objective of this consensus document is to broaden the perspective on clinical management of genitourinary syndrome of menopause to include androgens. METHODS: A modified Delphi method was used to reach consensus among the 14 international panelists representing multiple disciplines and societies. RESULTS: Menopause-related genitourinary symptoms affect over 50% of midlife and older women. These symptoms have a marked impact on sexual functioning, daily activities, emotional well-being, body image, and interpersonal relations...
June 4, 2018: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/29869453/insights-into-the-role-of-androgen-receptor-in-human-testicular-peritubular-cells
#17
C Mayer, M Adam, L Walenta, N Schmid, H Heikelä, K Schubert, F Flenkenthaler, K-G Dietrich, S Gruschka, G J Arnold, T Fröhlich, J U Schwarzer, F M Köhn, L Strauss, H Welter, M Poutanen, A Mayerhofer
Contractile smooth muscle-like peritubular cells build the wall of seminiferous tubules in men. They are crucial for sperm transport and complement the functions of Sertoli cells by secreting factors, including glial cell line-derived neurotrophic factor. Previous studies revealed that they also secrete the chemokine C-X-C motif chemokine ligand 12 (CXCL12), which has known roles in spermatogenesis. Peritubular cells express the androgen receptor (AR), which is retained in isolated human testicular peritubular cells...
June 5, 2018: Andrology
https://www.readbyqxmd.com/read/29863451/tailoring-adjuvant-endocrine-therapy-for-premenopausal-breast-cancer
#18
Prudence A Francis, Olivia Pagani, Gini F Fleming, Barbara A Walley, Marco Colleoni, István Láng, Henry L Gómez, Carlo Tondini, Eva Ciruelos, Harold J Burstein, Hervé R Bonnefoi, Meritxell Bellet, Silvana Martino, Charles E Geyer, Matthew P Goetz, Vered Stearns, Graziella Pinotti, Fabio Puglisi, Simon Spazzapan, Miguel A Climent, Lorenzo Pavesi, Thomas Ruhstaller, Nancy E Davidson, Robert Coleman, Marc Debled, Stefan Buchholz, James N Ingle, Eric P Winer, Rudolf Maibach, Manuela Rabaglio-Poretti, Barbara Ruepp, Angelo Di Leo, Alan S Coates, Richard D Gelber, Aron Goldhirsch, Meredith M Regan
Background In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received the aromatase inhibitor exemestane plus ovarian suppression than among those who received tamoxifen plus ovarian suppression. The addition of ovarian suppression to tamoxifen did not result in significantly lower recurrence rates than those with tamoxifen alone. Here, we report the updated results from the two trials...
June 4, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29862427/tamoxifen-and-the-risk-of-parkinsonism-a-case-non-case-study
#19
François Montastruc, Farzin Khosrow-Khavar, Sibylle de Germay, Christel Renoux, Vanessa Rousseau, Geneviève Durrieu, Marion Montastruc, Olivier Rascol, Agnès Sommet, Maryse Lapeyre-Mestre, Justine Benevent, Jean-Louis Montastruc
BACKGROUND: Three studies have suggested a potential positive association between the use of tamoxifen in breast cancer and Parkinsonism, mainly after long-term exposure. OBJECTIVES: To explore this potential signal, we performed a case/non-case study using the World Health Organization Global Individual Case Safety Reports (ICSRs) database, VigiBase® between 1979 and 2018. METHODS: Among women ≥ 55 years, we measured the risk of reporting "Parkinsonism" compared with all other adverse drug reactions [as a reporting odds ratio (ROR 95% CI)] for tamoxifen compared to all other drugs or aromatase inhibitors...
June 3, 2018: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29862411/everolimus-plus-exemestane-vs-everolimus-or-capecitabine-monotherapy-for-estrogen-receptor-positive-her2-negative-advanced-breast-cancer-the-bolero-6-randomized-clinical-trial
#20
Guy Jerusalem, Richard H de Boer, Sara Hurvitz, Denise A Yardley, Elena Kovalenko, Bent Ejlertsen, Sibel Blau, Mustafa Özgüroglu, László Landherr, Marianne Ewertz, Tetiana Taran, Jenna Fan, Florence Noel-Baron, Anne-Laure Louveau, Howard Burris
Importance: Everolimus plus exemestane and capecitabine are approved second-line therapies for advanced breast cancer. Objective: A postapproval commitment to health authorities to estimate the clinical benefit of everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Design: Open-label, randomized, phase 2 trial of treatment effects in postmenopausal women with advanced breast cancer that had progressed during treatment with nonsteroidal aromatase inhibitors...
June 3, 2018: JAMA Oncology
keyword
keyword
4026
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"